Was PTC Ther­a­peu­tics play­ing games when it tried to defuse the de­flaza­cort con­tro­ver­sy with a $35,000 an­nu­al price?

When PTC Ther­a­peu­tics $PTCT CEO Stu­art Peltz rolled out the biotech’s Q1 re­port this morn­ing, he not­ed that com­pa­ny ex­ecs came up with what they be­lieve is a “sus­tain­able” price for the cheap, old steroid ac­quired from the con­tro­ver­sial crew at Marathon Phar­ma­ceu­ti­cals for $140 mil­lion up front and tar­get­ed at the Duchenne com­mu­ni­ty in the US.

The net price, he said, would av­er­age $35,000 a year for a pa­tient that weighed 25 kilo­grams, or 55 pounds.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.